Exact Mass: 917.5374476

Exact Mass Matches: 917.5374476

Found 47 metabolites which its exact mass value is equals to given mass value 917.5374476, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

PE(DiMe(13,5)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

(2-aminoethoxy)[(2R)-2-{[(5Z,7R,8E,10Z,13Z,15E,17S,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoyl]oxy}-3-{[13-(3,4-dimethyl-5-pentylfuran-2-yl)tridecanoyl]oxy}propoxy]phosphinic acid

C51H84NO11P (917.5781684)


PE(DiMe(13,5)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(DiMe(13,5)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)), in particular, consists of one chain of one 14,17-epoxy-15-methyldocosa-14,16-dienoyl at the C-1 position and one chain of Resolvin D5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   

PE(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/DiMe(13,5))

(2-aminoethoxy)[(2R)-3-{[(5Z,7S,8E,10Z,13Z,15E,17R,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoyl]oxy}-2-{[13-(3,4-dimethyl-5-pentylfuran-2-yl)tridecanoyl]oxy}propoxy]phosphinic acid

C51H84NO11P (917.5781684)


PE(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/DiMe(13,5)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/DiMe(13,5)), in particular, consists of one chain of one Resolvin D5 at the C-1 position and one chain of 14,17-epoxy-15-methyldocosa-14,16-dienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   

PE(DiMe(13,5)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

(2-aminoethoxy)[(2R)-2-{[(4Z,7Z,10R,11E,13Z,15E,17S,19Z)-10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoyl]oxy}-3-{[13-(3,4-dimethyl-5-pentylfuran-2-yl)tridecanoyl]oxy}propoxy]phosphinic acid

C51H84NO11P (917.5781684)


PE(DiMe(13,5)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(DiMe(13,5)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)), in particular, consists of one chain of one 14,17-epoxy-15-methyldocosa-14,16-dienoyl at the C-1 position and one chain of Protectin DX at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   

PE(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/DiMe(13,5))

(2-aminoethoxy)[(2R)-3-{[(4Z,7Z,10S,11E,13Z,15E,17R,19Z)-10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoyl]oxy}-2-{[13-(3,4-dimethyl-5-pentylfuran-2-yl)tridecanoyl]oxy}propoxy]phosphinic acid

C51H84NO11P (917.5781684)


PE(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/DiMe(13,5)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/DiMe(13,5)), in particular, consists of one chain of one Protectin DX at the C-1 position and one chain of 14,17-epoxy-15-methyldocosa-14,16-dienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   

Solasodine base + 2H, 1O, O-Hex-Hex-Hex

Solasodine base + 2H, 1O, O-Hex-Hex-Hex

C45H75NO18 (917.4983890000001)


Annotation level-3

   

cyclo(L-Pro-L-Trp-L-Ile-L-Pro-L-Leu-L-Thr-L-Pro-L-Leu)|phakellistatin 15

cyclo(L-Pro-L-Trp-L-Ile-L-Pro-L-Leu-L-Thr-L-Pro-L-Leu)|phakellistatin 15

C48H71N9O9 (917.5374476)


   
   

Hydroxytomatidenol-tri-O-hexoside

Hydroxytomatidenol-tri-O-hexoside

C45H75NO18 (917.4983890000001)


   
   

H-Ser-Gln-Asn-Phe-psi(CH2NH)Pro-Ile-Val-Gln-OH

H-Ser-Gln-Asn-Phe-psi(CH2NH)Pro-Ile-Val-Gln-OH

C42H67N11O12 (917.4970422)


   

(4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-[(2R,3R,4R,5S,6R)-5-[(2S,4R,5S,6S)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-[[(2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-7-(2-hydroxyethyl)-5,9,13-trimethyl-1-oxacyclohexadeca-11,13-diene-2,10-dione

(4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-[(2R,3R,4R,5S,6R)-5-[(2S,4R,5S,6S)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-[[(2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-7-(2-hydroxyethyl)-5,9,13-trimethyl-1-oxacyclohexadeca-11,13-diene-2,10-dione

C46H79NO17 (917.5347724000001)


   
   

PE(DiMe(13,5)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

PE(DiMe(13,5)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C51H84NO11P (917.5781684)


   

PE(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/DiMe(13,5))

PE(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/DiMe(13,5))

C51H84NO11P (917.5781684)


   

PE(DiMe(13,5)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

PE(DiMe(13,5)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C51H84NO11P (917.5781684)


   

PE(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/DiMe(13,5))

PE(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/DiMe(13,5))

C51H84NO11P (917.5781684)


   

2-[[(2R)-2-[(2R)-2-amino-3-[(4S,5R,6E,8E,10Z,13Z)-1-carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl]sulfanylpropanoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-2-[(2R)-2-amino-3-[(4S,5R,6E,8E,10Z,13Z)-1-carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl]sulfanylpropanoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C47H86N2O11PS+ (917.5689636000001)


   

2-[[(2R)-3-[(2R)-2-amino-3-[(4S,5R,6E,8E,10Z,13Z)-1-carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl]sulfanylpropanoyl]oxy-2-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-3-[(2R)-2-amino-3-[(4S,5R,6E,8E,10Z,13Z)-1-carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl]sulfanylpropanoyl]oxy-2-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C47H86N2O11PS+ (917.5689636000001)


   

1-stearoyl-2-(15-HpETE)-PI(1-)

1-stearoyl-2-(15-HpETE)-PI(1-)

C47H82O15P- (917.5391052)


   

Ac-Cha-Arg-MePhg-Met-Ala-Ser-tLeu-NH2

Ac-Cha-Arg-MePhg-Met-Ala-Ser-tLeu-NH2

C43H71N11O9S (917.5156676)


   

(8Z,11Z,14Z,17Z,20Z,23Z)-N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytrideca-4,8-dien-2-yl]hexacosa-8,11,14,17,20,23-hexaenamide

(8Z,11Z,14Z,17Z,20Z,23Z)-N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytrideca-4,8-dien-2-yl]hexacosa-8,11,14,17,20,23-hexaenamide

C51H83NO13 (917.5864108)


   

(3Z,6Z,9Z,12Z,15Z)-N-[1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxynonan-2-yl]octadeca-3,6,9,12,15-pentaenamide

(3Z,6Z,9Z,12Z,15Z)-N-[1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxynonan-2-yl]octadeca-3,6,9,12,15-pentaenamide

C45H75NO18 (917.4983890000001)


   

(9Z,12Z,15Z,18Z,21Z,24Z,27Z)-N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxynon-4-en-2-yl]triaconta-9,12,15,18,21,24,27-heptaenamide

(9Z,12Z,15Z,18Z,21Z,24Z,27Z)-N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxynon-4-en-2-yl]triaconta-9,12,15,18,21,24,27-heptaenamide

C51H83NO13 (917.5864108)


   

(6Z,9Z,12Z,15Z,18Z,21Z)-N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxypentadeca-4,8-dien-2-yl]tetracosa-6,9,12,15,18,21-hexaenamide

(6Z,9Z,12Z,15Z,18Z,21Z)-N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxypentadeca-4,8-dien-2-yl]tetracosa-6,9,12,15,18,21-hexaenamide

C51H83NO13 (917.5864108)


   

(7Z,10Z,13Z,16Z,19Z,22Z,25Z)-N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyundec-4-en-2-yl]octacosa-7,10,13,16,19,22,25-heptaenamide

(7Z,10Z,13Z,16Z,19Z,22Z,25Z)-N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyundec-4-en-2-yl]octacosa-7,10,13,16,19,22,25-heptaenamide

C51H83NO13 (917.5864108)


   

(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z)-N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxynonan-2-yl]triaconta-6,9,12,15,18,21,24,27-octaenamide

(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z)-N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxynonan-2-yl]triaconta-6,9,12,15,18,21,24,27-octaenamide

C51H83NO13 (917.5864108)


   

(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytridec-4-en-2-yl]hexacosa-5,8,11,14,17,20,23-heptaenamide

(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytridec-4-en-2-yl]hexacosa-5,8,11,14,17,20,23-heptaenamide

C51H83NO13 (917.5864108)


   

(4Z,7Z,10Z,13Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyundec-4-en-2-yl]hexadeca-4,7,10,13-tetraenamide

(4Z,7Z,10Z,13Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyundec-4-en-2-yl]hexadeca-4,7,10,13-tetraenamide

C45H75NO18 (917.4983890000001)


   

(3Z,6Z,9Z,12Z,15Z)-N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyhenicosa-4,8,12-trien-2-yl]octadeca-3,6,9,12,15-pentaenamide

(3Z,6Z,9Z,12Z,15Z)-N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyhenicosa-4,8,12-trien-2-yl]octadeca-3,6,9,12,15-pentaenamide

C51H83NO13 (917.5864108)


   

(7Z,10Z,13Z,16Z,19Z)-N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyheptadeca-4,8,12-trien-2-yl]docosa-7,10,13,16,19-pentaenamide

(7Z,10Z,13Z,16Z,19Z)-N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyheptadeca-4,8,12-trien-2-yl]docosa-7,10,13,16,19-pentaenamide

C51H83NO13 (917.5864108)


   

(4Z,7Z,10Z,13Z,16Z,19Z)-N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyheptadeca-4,8-dien-2-yl]docosa-4,7,10,13,16,19-hexaenamide

(4Z,7Z,10Z,13Z,16Z,19Z)-N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyheptadeca-4,8-dien-2-yl]docosa-4,7,10,13,16,19-hexaenamide

C51H83NO13 (917.5864108)


   

(9Z,12Z,15Z,18Z,21Z)-N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxypentadeca-4,8,12-trien-2-yl]tetracosa-9,12,15,18,21-pentaenamide

(9Z,12Z,15Z,18Z,21Z)-N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxypentadeca-4,8,12-trien-2-yl]tetracosa-9,12,15,18,21-pentaenamide

C51H83NO13 (917.5864108)


   

(5Z,8Z,11Z,14Z,17Z)-N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxynonadeca-4,8,12-trien-2-yl]icosa-5,8,11,14,17-pentaenamide

(5Z,8Z,11Z,14Z,17Z)-N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxynonadeca-4,8,12-trien-2-yl]icosa-5,8,11,14,17-pentaenamide

C51H83NO13 (917.5864108)


   

(6Z,9Z,12Z,15Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxynon-4-en-2-yl]octadeca-6,9,12,15-tetraenamide

(6Z,9Z,12Z,15Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxynon-4-en-2-yl]octadeca-6,9,12,15-tetraenamide

C45H75NO18 (917.4983890000001)


   
   
   
   
   
   
   
   

(Sar1,Ile4,8)-Angiotensin II

(Sar1,Ile4,8)-Angiotensin II

C43H75N13O9 (917.5810420000001)


(Sar1,Ile4,8)-Angiotensin II is a functionally selective angiotensin II type 1 receptor (AT1R) agonist. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β[1]. (Sar1,Ile4,8)-Angiotensin II is a functionally selective angiotensin II type 1 receptor (AT1R) agonist. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β[1].

   

9-({5-[(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy]-4-(dimethylamino)-6-methyloxan-2-yl}oxy)-3-ethyl-7-hydroxy-2-{[(5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl)oxy]methyl}-10-(2-hydroxyethyl)-8,12,16-trimethyl-4,17-dioxabicyclo[14.1.0]heptadec-14-ene-5,13-dione

9-({5-[(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy]-4-(dimethylamino)-6-methyloxan-2-yl}oxy)-3-ethyl-7-hydroxy-2-{[(5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl)oxy]methyl}-10-(2-hydroxyethyl)-8,12,16-trimethyl-4,17-dioxabicyclo[14.1.0]heptadec-14-ene-5,13-dione

C46H79NO17 (917.5347724000001)


   

(3s,6s,12s,15s,18s,24s,27s,30s)-24-[(2s)-butan-2-yl]-5,14,17,26,29-pentahydroxy-12-[(1r)-1-hydroxyethyl]-27-(1h-indol-3-ylmethyl)-3,15-bis(2-methylpropyl)-1,4,10,13,16,22,25,28-octaazatetracyclo[28.3.0.0⁶,¹⁰.0¹⁸,²²]tritriaconta-4,13,16,25,28-pentaene-2,11,23-trione

(3s,6s,12s,15s,18s,24s,27s,30s)-24-[(2s)-butan-2-yl]-5,14,17,26,29-pentahydroxy-12-[(1r)-1-hydroxyethyl]-27-(1h-indol-3-ylmethyl)-3,15-bis(2-methylpropyl)-1,4,10,13,16,22,25,28-octaazatetracyclo[28.3.0.0⁶,¹⁰.0¹⁸,²²]tritriaconta-4,13,16,25,28-pentaene-2,11,23-trione

C48H71N9O9 (917.5374476)


   

(4r,5s,6s,7r,9r,11e,13e,15r,16r)-6-{[(2r,3r,4r,5s,6r)-5-{[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy}-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-16-ethyl-4-hydroxy-15-({[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-7-(2-hydroxyethyl)-5,9,13-trimethyl-1-oxacyclohexadeca-11,13-diene-2,10-dione

(4r,5s,6s,7r,9r,11e,13e,15r,16r)-6-{[(2r,3r,4r,5s,6r)-5-{[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy}-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-16-ethyl-4-hydroxy-15-({[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-7-(2-hydroxyethyl)-5,9,13-trimethyl-1-oxacyclohexadeca-11,13-diene-2,10-dione

C46H79NO17 (917.5347724000001)


   

5,14,17,26,29-pentahydroxy-12-(1-hydroxyethyl)-27-(1h-indol-3-ylmethyl)-3,15-bis(2-methylpropyl)-24-(sec-butyl)-1,4,10,13,16,22,25,28-octaazatetracyclo[28.3.0.0⁶,¹⁰.0¹⁸,²²]tritriaconta-4,13,16,25,28-pentaene-2,11,23-trione

5,14,17,26,29-pentahydroxy-12-(1-hydroxyethyl)-27-(1h-indol-3-ylmethyl)-3,15-bis(2-methylpropyl)-24-(sec-butyl)-1,4,10,13,16,22,25,28-octaazatetracyclo[28.3.0.0⁶,¹⁰.0¹⁸,²²]tritriaconta-4,13,16,25,28-pentaene-2,11,23-trione

C48H71N9O9 (917.5374476)